• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较口腔扁平苔藓和口腔类天疱疮中生物标志物的表达。

Comparison of biomarker expression in oral lichen planus and oral lichenoid lesions.

机构信息

Department of Oral Pathology, Wroclaw Medical University, Poland.

Department of Immunopathology and Molecular Biology, Wroclaw Medical University, Poland.

出版信息

Adv Clin Exp Med. 2022 Dec;31(12):1327-1334. doi: 10.17219/acem/152429.

DOI:10.17219/acem/152429
PMID:36047896
Abstract

BACKGROUND

Oral lichen planus (OLP) and oral lichenoid lesions (OLL) comprise a group of oral mucosal disorders that have similar clinical and histological features.

OBJECTIVES

To compare the levels of investigated biomarkers in biopsied OLP and OLL, and to determine the pattern of biomarkers, which could be useful for the biological characterization of these 2 disorders.

MATERIAL AND METHODS

A total of 56 biopsy specimens in 2 groups were analyzed in this study. One group consisted of 25 idiopathic OLP lesions, and the other included 31 OLL from patients treated with antihypertensive and cardiac medications. The expression of protein p53, topoisomerase I (topo I), heat shock protein 90 (HSP90), and E-cadherin was analyzed using immunohistochemistry.

RESULTS

The p53 protein expression showed a trend to a positive correlation with topo I expression in the total sample (p = 0.067, R = 0.25). The p53 protein and HSP90 expression was higher in the OLL group compared to the OLP group, but the difference was not statistically significant. No association was found between topo I and E-cadherin expression for either the OLP or OLL group.

CONCLUSIONS

The findings of this study suggest that the slightly higher protein p53 and HSP90 expression in the OLL group might be caused by the medications used. The slight association between p53 and topo I expression indicates that the cooperation between these proteins might be essential for the growth of OLP/OLL in general. We conclude that the overexpression of p53 protein and high expression of topo I found in both types of lesions might induce their biologically aggressive behavior.

摘要

背景

口腔扁平苔藓(OLP)和口腔类扁平苔藓病变(OLL)是一组具有相似临床和组织学特征的口腔黏膜疾病。

目的

比较活检 OLP 和 OLL 中研究生物标志物的水平,并确定这些生物标志物的模式,这可能有助于这两种疾病的生物学特征分析。

材料和方法

本研究分析了两组共 56 个活检标本。一组包括 25 个特发性 OLP 病变,另一组包括 31 个接受抗高血压和心脏药物治疗的 OLL 患者。使用免疫组织化学法分析蛋白质 p53、拓扑异构酶 I(topo I)、热休克蛋白 90(HSP90)和 E-钙黏蛋白的表达。

结果

总样本中 p53 蛋白表达与 topo I 表达呈正相关趋势(p = 0.067,R = 0.25)。与 OLP 组相比,OLL 组的 p53 蛋白和 HSP90 表达更高,但差异无统计学意义。OLP 或 OLL 组中,topo I 和 E-钙黏蛋白的表达之间均无相关性。

结论

本研究结果表明,OLL 组中 p53 蛋白和 HSP90 表达略高可能是由于使用了药物。p53 与 topo I 表达之间的轻微相关性表明,这些蛋白之间的合作可能对 OLP/OLL 的生长至关重要。我们得出结论,两种病变中 p53 蛋白的过度表达和 topo I 的高表达可能导致其生物学侵袭性行为。

相似文献

1
Comparison of biomarker expression in oral lichen planus and oral lichenoid lesions.比较口腔扁平苔藓和口腔类天疱疮中生物标志物的表达。
Adv Clin Exp Med. 2022 Dec;31(12):1327-1334. doi: 10.17219/acem/152429.
2
Direct Immunofluorescence as a Helpful Tool for the Differential Diagnosis of Oral Lichen Planus and Oral Lichenoid Lesions.直接免疫荧光法作为口腔扁平苔藓和口腔苔藓样病变鉴别诊断的有用工具
Am J Dermatopathol. 2018 Jul;40(7):491-497. doi: 10.1097/DAD.0000000000001071.
3
Lichenoid dysplasia revisited - evidence from a review of Indian archives.再探苔藓样发育异常——来自印度档案回顾的证据
J Oral Pathol Med. 2015 Aug;44(7):507-14. doi: 10.1111/jop.12258. Epub 2014 Sep 15.
4
Evaluation of proliferative potential in oral lichen planus and oral lichenoid lesions using immunohistochemical expression of p53 and Ki67.利用p53和Ki67的免疫组化表达评估口腔扁平苔藓和口腔苔藓样病变的增殖潜能。
Oral Oncol. 2006 May;42(5):475-80. doi: 10.1016/j.oraloncology.2005.09.012. Epub 2005 Dec 20.
5
Clinical features of oral lichen planus and oral lichenoid lesions: an oral pathologist's perspective.口腔扁平苔藓和口腔类扁平苔藓病变的临床特征:口腔病理学家视角。
Braz Dent J. 2022 May-Jun;33(3):67-73. doi: 10.1590/0103-6440202204426.
6
Severity of oral lichen planus and oral lichenoid lesions is associated with anxiety.口腔扁平苔藓和口腔类扁平苔藓病变的严重程度与焦虑有关。
Clin Oral Investig. 2019 Dec;23(12):4441-4448. doi: 10.1007/s00784-019-02892-2. Epub 2019 Apr 15.
7
Oral lichen planus (OLP), oral lichenoid lesions (OLL), oral dysplasia, and oral cancer: retrospective analysis of clinicopathological data from 2002-2011.口腔扁平苔藓(OLP)、口腔苔藓样病变(OLL)、口腔发育异常及口腔癌:2002年至2011年临床病理数据的回顾性分析
Oral Maxillofac Surg. 2015 Jun;19(2):149-56. doi: 10.1007/s10006-014-0469-y. Epub 2014 Oct 14.
8
The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective study.口腔扁平苔藓和口腔苔藓样病变的潜在癌前特征:一项前瞻性研究。
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Aug;96(2):164-71. doi: 10.1016/s1079-2104(03)00305-6.
9
The role of CD68+ and CD163+ macrophages in immunopathogenesis of oral lichen planus and oral lichenoid lesions.CD68+ 和 CD163+ 巨噬细胞在口腔扁平苔藓和口腔类扁平苔藓病变免疫发病机制中的作用。
Immunobiology. 2021 May;226(3):152072. doi: 10.1016/j.imbio.2021.152072. Epub 2021 Feb 23.
10
Immunohistochemical evaluation of Langerhans cells in oral lichen planus and oral lichenoid lesions.口腔扁平苔藓和口腔类扁平苔藓病变中朗格汉斯细胞的免疫组织化学评估。
Arch Oral Biol. 2021 Apr;124:105027. doi: 10.1016/j.archoralbio.2020.105027. Epub 2020 Dec 8.

引用本文的文献

1
Circulating Antibodies Against DSG1 and DSG3 in Patients with Oral Lichen Planus: A Scoping Review.口腔扁平苔藓患者中抗桥粒芯糖蛋白1和桥粒芯糖蛋白3的循环抗体:一项范围综述
Antibodies (Basel). 2025 Jun 18;14(2):51. doi: 10.3390/antib14020051.
2
Implications of p53 protein upregulation in oral lichen planus: a systematic review and meta-analysis.p53 蛋白上调在口腔扁平苔藓中的意义:系统评价和荟萃分析。
Med Oral Patol Oral Cir Bucal. 2024 Nov 1;29(6):e832-e842. doi: 10.4317/medoral.26808.
3
A Molecular Hypothesis on Malignant Transformation of Oral Lichen Planus: A Systematic Review and Meta-Analysis of Cancer Hallmarks Expression in This Oral Potentially Malignant Disorder.
口腔扁平苔藓恶性转化的分子假说:对这种口腔潜在恶性疾病中癌症特征表达的系统评价和荟萃分析
Cancers (Basel). 2024 Jul 23;16(15):2614. doi: 10.3390/cancers16152614.